Hippocratic AI, a leader in healthcare-focused large language models (LLMs) for non-diagnostic, patient-facing clinical tasks, has raised $141 million in a Series B funding round led by Kleiner Perkins, bringing its valuation to $1.64 billion. Existing investors, including A16z, General Catalyst, NVIDIA, and Universal Health Services, also participated, contributing at or above their pro-rata share. This funding, secured just nine months after the company’s Series A round, will drive Hippocratic AI’s expansion into pharmaceuticals, payors, and global markets such as EMEA, Southeast Asia, and Latin America. The company’s Polaris 2.0 architecture, which increased model parameters from 1.1 trillion to 3.7 trillion, ensures safety parity with human clinicians—a milestone achieved in collaboration with founding health systems like OhioHealth and Memorial Hermann.
Hippocratic AI also launched its AI Agent App Store, enabling licensed clinicians to design and monetize AI agents tailored to specific healthcare needs. These agents, which have already completed hundreds of thousands of patient interactions with an average satisfaction score of 8.7 out of 10, address tasks like chronic care management and patient education. CEO Munjal Shah emphasized the company’s mission to achieve “healthcare abundance” through scalable AI solutions, supported by partnerships with 23 healthcare organizations. Kleiner Perkins partner Mamoon Hamid highlighted the vast market potential of generative AI in addressing healthcare staffing shortages, positioning Hippocratic AI as a pioneer in transforming patient care and operational efficiency.